|Bid||17.89 x 2200|
|Ask||18.01 x 900|
|Day's Range||17.86 - 18.33|
|52 Week Range||14.51 - 41.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Acadia Pharmaceuticals and Celgene Corporation have both significantly underperformed the broader market this year. Are they now outstanding bargains?
The San Diego-based company said it had a loss of 44 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 25) Eleven Biotherapeutics Inc (NASDAQ: EBIO ) Integra Lifesciences ...
While a number of companies in the biotechnology space staged a strong start to the week, some others didn’t fare so well. One that falls into the latter category is Acadia Pharmaceuticals (NASDAQ:ACAD). On Wednesday morning, Acadia was trading for in and around $20 a share. By the close of play on Wednesday, this had […] The post Here’s What Just Happened With Acadia appeared first on Market Exclusive.
The U.S. Food and Drug Administration said on Wednesday it was reviewing Acadia Pharmaceuticals' Parkinson's medication, the only approved drug used to treat hallucinations and delusions associated with the disease. CNN first reported that FDA was re-examining the safety of Acadia's Nuplazid, which was approved by the agency even though there were concerns that not enough was known about the drug's risks. CNN also reported earlier this month that the FDA received a spike in "adverse events reports" among those using the drug, including death, but those reports do not necessarily prove that the drug caused the event.
Shares tumble after a major news outlet reports that the FDA is re-examining the safety profile of Acadia's drug Nuplazid. Here's what investors need to know.
Acadia Pharmaceuticals shares plunged on a report the Food and Drug Administration will re-examine its only drug. Lawmakers grilled FDA Commissioner Scott Gottlieb about why the agency approved Nuplazid, which treats psychosis associated with Parkinson's disease. Acadia Pharmaceuticals ACAD shares plunged 22 percent Wednesday after a report the Food and Drug Administration will re-examine its only drug.
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. A lot of people feel world commerce is going to slow down, a lot of different crosscurrents because of tariffs.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ACAD totaled $633 million.
Understanding ACADIA Pharmaceuticals Inc’s (NASDAQ:ACAD) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock was falling hard today on an article about its drug Nuplazid. Nuplazid is a drug that was given approval by the U.S. Food and Drug Administration (FDA) and started being sold to customers in June 2016. The drug was given fast-track approval by the FDA, despite concerns that it may not actually help those suffering from Parkinson’s disease.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) faded 24 percent Monday after CNN exposed the deaths of more than 700 Nuplazid patients since the drug’s June 2016 launch. The U.S. Food and Drug Administration ...
Traders flee after a troublesome news report emerged related to the company's only drug, Nuplazid. Here's what investors need to know.